NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nyxoah SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 26, 2026
$0.95−0.16 (-14.05%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Gross profit | +113.1% | +48.4% | +176.7% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -111.0% | |
| Return on assets | – | – | -65.1% | |
| Current ratio | – | – | 1.25 | |
| Interest coverage | – | -11.3× | -7.2× | |
| Diluted shares | – | 18M | 38M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nyxoah generated €217.08M from operations and spent €6.83M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€217.08M
Used
€6.83M
Capital expenditure€6.83M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-€90.09M
- Cash generatingOperating cash flow above zero-€68.98M
- Return on assets improvedROA up on the prior year-47.7% → -56.9%
- Earnings backed by cashOperating cash flow above net income-€68.98M vs -€90.09M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.56 → 1.25
- No dilutionShare count did not rise33M → 38M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –